Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News Nov 14, 2022 Abeona Therapeutics Reports Third Quarter 2022 Financial Results View Press Release Nov 3, 2022 Abeona Therapeutics Announces $35 Million Private Placement Financing View Press Release Nov 3, 2022 Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101 View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
